Etaracizumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Etaracizumab
Accession Number
DB12213
Type
Biotech
Groups
Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Description

Etaracizumab has been investigated for the treatment of Psoriasis, Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer, and Stage III Renal Cell Cancer.

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
Not Available
External IDs
MEDI-522 / MEDI522
Categories
UNII
41W9MFI160
CAS number
892553-42-3

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Etaracizumab.
AbituzumabThe risk or severity of adverse effects can be increased when Etaracizumab is combined with Abituzumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Etaracizumab.
AdecatumumabThe risk or severity of adverse effects can be increased when Adecatumumab is combined with Etaracizumab.
AducanumabThe risk or severity of adverse effects can be increased when Etaracizumab is combined with Aducanumab.
AfelimomabThe risk or severity of adverse effects can be increased when Afelimomab is combined with Etaracizumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Etaracizumab.
AlirocumabThe risk or severity of adverse effects can be increased when Alirocumab is combined with Etaracizumab.
AmatuximabThe risk or severity of adverse effects can be increased when Etaracizumab is combined with Amatuximab.
AMG 108The risk or severity of adverse effects can be increased when AMG 108 is combined with Etaracizumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911300
Wikipedia
Etaracizumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentMalignancies1
1CompletedTreatmentMalignant Lymphomas / Small Intestine Cancer / Unspecified Adult Solid Tumor, Protocol Specific1
1CompletedTreatmentMalignant Melanoma1
1, 2CompletedTreatmentColorectal Cancers1
1, 2CompletedTreatmentMalignancies1
1, 2TerminatedTreatmentRenal Cell Adenocarcinoma / Renal Cell Cancer, Recurrent / Stage III Renal Cell Cancer / Stage IV Renal Cell Cancer1
2CompletedTreatmentProstate Cancer1
2CompletedTreatmentPsoriasis1
2CompletedTreatmentRheumatoid Arthritis1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Drug created on October 20, 2016 15:37 / Updated on November 02, 2018 07:21